Once-daily oral drug shows injectable-level efficacy against hereditary swelling disorder
Pharvaris reported positive pivotal trial results for an extended-release version of deucrictibant, a once-daily pill designed to prevent swelling attacks in patients with a rare genetic disease. The company claims the treatment achieved efficacy comparable to injectable therapies, leading to a sharp rise in its stock price. Further regulatory steps are expected as the drug moves toward potential approval.
Pharvaris has announced encouraging late-stage trial data for its oral medication, deucrictibant. The extended-release formulation is intended for daily use to stave off acute attacks associated with a rare inherited condition.
The favorable efficacy profile, which reportedly matches current injectable standards, prompted a notable surge in the company's market value. With these results in hand, the developer is now preparing for formal regulatory submissions to seek approval for the therapy.
For patients living with this hereditary swelling disorder, a convenient daily pill could significantly ease treatment burden compared to regular injections. If approved, this therapy may improve adherence and quality of life, potentially reducing emergency episodes. The broader impact also extends to healthcare systems, which could see shifts in administration costs and patient management. However, long-term safety and real-world effectiveness remain to be fully established.